scispace - formally typeset
E

E. Del Ninno

Researcher at University of Milan

Publications -  36
Citations -  1860

E. Del Ninno is an academic researcher from University of Milan. The author has contributed to research in topics: Cirrhosis & Lamivudine. The author has an hindex of 15, co-authored 36 publications receiving 1839 citations.

Papers
More filters
Journal ArticleDOI

Prevalence of antibodies to hepatitis c virus in italian patients with hepatocellular carcinoma

TL;DR: Data indicate that, in Italy, HCV is an important factor associated with hepatocellular carcinoma and non-A, non-B chronic hepatitis.
Journal ArticleDOI

Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a.

TL;DR: The occurrence of thyroid abnormalities and the appearance of organ- and non-organ-specific autoantibodies during long-term recombinant interferon alpha-2a (IFN-alpha) therapy were studied in 86 and 51 consecutive outpatients with hepatitis C and B virus-related chronic active hepatitis (CAH-HCV and CAH-HBV).
Journal ArticleDOI

A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum.

TL;DR: A 24‐month course of treatment with 6 MU IFN‐α2b was well tolerated by most patients, led to sustained suppression of HBV in one third, and attenuated hepatitis in 81% of patients.
Journal ArticleDOI

Influence of different hepatitis C virus genotypes on the course of asymptomatic hepatitis C virus infection

TL;DR: Genotype 2 was as frequent as genotype 1 but associated with less liver function impairment and the high prevalence of chronic hepatitis should be considered in counseling viremic asymptomatic donors.
Journal ArticleDOI

High prevalence of multinodular hepatocellular carcinoma in patients with cirrhosis attributable to multiple risk factors.

TL;DR: It was concluded that multinodular HCC was underdetected by real time US; it prevailed among patients with multiple risk factors; in these patients, screening with US exams every 6 months may be inadequate for early detection of liver cancer.